Holen Sie sich die Stockscreener-App
1.72
6.83%
0.11
Schlusskurs vom Vortag:
$1.61
Offen:
$1.63
24-Stunden-Volumen:
246.81K
Relative Volume:
0.48
Marktkapitalisierung:
$30.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.70M
KGV:
-0.4943
EPS:
-3.4798
Netto-Cashflow:
$-16.66M
1W Leistung:
+47.64%
1M Leistung:
+34.37%
6M Leistung:
-65.60%
1J Leistung:
-79.10%
1-Tages-Spanne:
$1.57
$1.7275
1-Wochen-Bereich:
$1.15
$1.7275
52-Wochen-Spanne:
$0.89
$13.48
Cel-Sci Corp. Stock (CVM) Company Profile
Firmenname
Cel-Sci Corp.
Sektor
Branche
Telefon
703-506-9460
Adresse
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.72 | 20.62M | 0 | -22.70M | -16.66M | -3.4798 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-01-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-02 | Eingeleitet | Dawson James | Buy |
Cel-Sci Corp. Aktie (CVM) Neueste Nachrichten
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CVM|CEL-SCI Corp|Price:1.180|Chg%:+0.010 - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Balance Sheet - TradingKey
TradingKey - TradingKey
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$1.155 | Cel-Sci Corporation (CVM) Stock Price Today - Binance
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CEL-SCI launches confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI (CVM) Initiates Global Study for Multikine in Head and N - GuruFocus
Cancer drug Multikine heads into 212-patient global trial for head and neck tumors - Stock Titan
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVMCel-Sci Corp Latest SEC Filings - Finviz
Form DEF 14A CEL-SCI CORPORATION For: 2 July By Investing.com - Investing.com Nigeria
[ARS] CEL SCI CORP SEC Filing - Stock Titan
Equity plans and pay votes at CEL-SCI (NYSE: CVM) 2026 annual meeting - Stock Titan
Form 4 CEL-SCI Corp For: 1 July By Investing.com - Investing.com UK
CEL SCI CORP (CVM) Chief Scientific Officer receives 2,307-share stock grant - Stock Titan
CEL SCI CORP (CVM) CFO receives 4,125-share stock grant in Form 4 - Stock Titan
CEL-SCI (CVM) CEO Kersten granted 5,192 common shares at $1.04 - Stock Titan
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - The Joplin Globe
CEL-SCI and Saudi Amarox seal Multikine pact at BIO 2026 - Stock Titan
CVM Q4 2024 Earnings: Narrower-Than-Expected Loss as Cel-Sci Advances PipelineProfitability Analysis - dars.gov.et
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month - MSN
BRIEF-CEL-SCI Announces Closing Of Offering - Dailyhunt
CEL-SCI Corp (CVM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CEL-SCI Corporation Announces $2.5 Million Stock Offering to Advance Multikine Cancer Immunotherapy 1 - Minichart
CEL-SCI closes $2.5M stock offering at $1 per share By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Advances Multikine for Head and Neck Cancer - GuruFocus
CEL-SCI Completes $2.5M Stock Offering at $1.00, Engages ThinkEquity as Placement Agent - TradingView
CEL-SCI (NYSE American: CVM) prices $2.5M best-efforts stock offering - Stock Titan
CEL-SCI closes $2.5M stock offering at $1 per share - Investing.com
Cancer immunotherapy firm CEL-SCI raises $2.5M for Multikine development - Stock Titan
CEL-SCI Announces Closing of Offering - Yahoo Finance
CEL-SCI to begin confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy - Yahoo Finance
[424B5] CEL SCI CORP Prospectus Supplement (Debt Securities) - Stock Titan
CEL-SCI Corporation (CVM) Prices Public Offering, Shares Drop in Premarket - GuruFocus
CEL-SCI stock sale prices $2.5M to fund Multikine work - Stock Titan
Finanzdaten der Cel-Sci Corp.-Aktie (CVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cel-Sci Corp.-Aktie (CVM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KERSTEN GEERT R | Chief Executive Officer |
May 13 '26 |
Buy |
1.19 |
100,000 |
119,000 |
222,497 |
| KERSTEN GEERT R | Chief Executive Officer |
Jan 22 '26 |
Buy |
5.26 |
38,023 |
200,001 |
120,815 |
| KERSTEN GEERT R | Chief Executive Officer |
Dec 04 '25 |
Buy |
5.96 |
8,389 |
49,998 |
81,794 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):